Compare DPRO & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DPRO | ACIU |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.7M | 213.3M |
| IPO Year | N/A | 2016 |
| Metric | DPRO | ACIU |
|---|---|---|
| Price | $7.86 | $3.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $15.67 | $10.00 |
| AVG Volume (30 Days) | ★ 2.5M | 418.4K |
| Earning Date | 11-12-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $5,335,758.00 | ★ $5,482,957.00 |
| Revenue This Year | $50.81 | N/A |
| Revenue Next Year | $149.77 | $644.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 26.74 | N/A |
| 52 Week Low | $1.63 | $1.43 |
| 52 Week High | $14.40 | $4.00 |
| Indicator | DPRO | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 43.67 | 48.39 |
| Support Level | $7.87 | $3.24 |
| Resistance Level | $8.70 | $3.90 |
| Average True Range (ATR) | 1.05 | 0.25 |
| MACD | -0.20 | -0.03 |
| Stochastic Oscillator | 2.44 | 16.67 |
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.